WorldCat Identities

Padró, Teresa

Overview
Works: 10 works in 10 publications in 1 language and 18 library holdings
Roles: Other, Contributor
Classifications: QH519, 616.3
Publication Timeline
.
Most widely held works by Teresa Padró
Molecular signature of coronary stent thrombosis: oxidative stress and innate immunity cells( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART) by Nelva Mata( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Erythrocyte-heme proteins and STEMI: implications in prognosis( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Lactobacillus plantarum CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response by Gemma Vilahur( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Antithrombotic therapy in obesity( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

The Role of Blood-Borne Microparticles in Inflammation and Hemostasis( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

5( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts the BiomarCaRE project by Dietrich Rothenbacher( )

1 edition published in 2020 in English and held by 1 WorldCat member library worldwide

Background: Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts. Methods: The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality. Results: The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3% and 7.4% in the population-based cohorts and 13.9% and 14.4% in the disease cohorts. CKD was an important independent risk factor for subsequent CVD events and mortality. For example, in the population-based cohorts, the HR for CVD mortality was 1.72 (95% CI 1.53 to 1.92) with creatinine-based CKD and it was 2.14 (95% CI 1.90 to 2.40) based on cystatin-based CKD compared to participants without CKD. In general, the HRs were higher for cystatin C-based CKD compared to creatinine-based CKD, for all three outcomes and risk increased clearly below the conventional threshold for CKD, also in older adults. Net reclassification indices were larger for a cystatin-C based CKD definition. Differences in HRs (between the two CKD measures) in the disease cohorts were less pronounced than in the population-based cohorts. Conclusion: CKD is an important risk factor for subsequent CVD events and total mortality. However, point estimates of creatinine- and cystatin C-based CKD differed considerably between low- and high-risk populations. Especially in low-risk settings, the use of cystatin C-based CKD may result in more accurate risk estimates and have better prognostic value
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.96 (from 0.88 for 5 ... to 0.97 for The Role o ...)

Languages
English (10)